We studied the activity of combined oxaliplatin and fluorouracil-leucovorin in 16 consecutive patients with advanced biliary tract adenocarcinomas. The disease control rate (responses and stable disease) was 56% (95% confidence interval, 29-84%) and the median overall survival time was 9.5 months (range 0.9-26.8+). Therefore, this regimen might be active in biliary adenocarcinomas with further evaluation necessary. © 2002 Cancer Research UK.
CITATION STYLE
Nehls, O., Klump, B., Arkenau, H. T., Hass, H. G., Greschniok, A., Gregor, M., & Porschen, R. (2002). Oxaliplatin, fluorouracil and leucovorin for advanced biliary system adenocarcinomas: A prospective phase II trial. British Journal of Cancer, 87(7), 702–704. https://doi.org/10.1038/sj.bjc.6600543
Mendeley helps you to discover research relevant for your work.